Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2012
  • Online publication date: August 2012

Chapter 14 - Clinical use of testosterone in hypogonadism and other conditions

Related content

Powered by UNSILO

14.9 References

AaronsonAJ, MorrisseyRP, NguyenCT, WillixR, SchwarzER (2011) Update on the safety of testosterone therapy in cardiac disease. Expert Opin Drug Saf 10:697–704
AdamopoulosDA, NicopoulouS, KapollaN, VassipoulosP, KaramertzanisM, KontogeorgosL (1995) Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia. Fertil Steril 64:818–824
AdamopoulosDA, NicopoulouSt, KapollaN, KaramertzanisM, AndreouE (1997) The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril 67:756–762
AkcamT, BoluE, MeratiAL, DurmusC, GerekM, OzkaptanY (2004) Voice changes after androgen therapy for hypogonadotrophic hypogonadism. Laryngoscope 114:1587–1591
AlbaneseA, StanhopeR (1995) Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 126:545–550
AlbaneseA, KewleyGD, LongA, PearlKN, RobinsDG, StanhopeR (1994) Oral treatment for constitutional delay of growth and puberty in boys: a randomized trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child 71:315–317
ArrigoT, CrisafulliG, SalzanoG, ZirilliG, De LucaF (2005) High-flow priapism in testosterone-treated boys with constitutional delay of growth and puberty may occur even when very low doses are used. J Endocrinol Invest 28:390–391
AttalP, ChansonP (2010) Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab 95:483–495
BagchusWM, HustR, MarisF, SchnabelPG, HouwingNS (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319–325
BasariaS, CovielloAD, TravisonTG, StorerTW, FarwellWR, JetteAM, EderR, TennstedtS, UlloorJ, ZhangA, ChoongK, LakshmanKM, MazerNA, MiciekR, KrasnoffJ, ElmiA, KnappPE, BrooksB, ApplemanE, AggarwalS, BhasinG, Hede-BrierleyL, BhatiaA, CollinsL, LeBrasseurN, FioreLD, BhasinS (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–222
BehreHM, BohmeyerJ, NieschlagE (1994) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 40:341–349
BehreHM, AbshagenK, OettelM, HüblerD, NieschlagE (1999a) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140:414–419
BehreHM, von EckardsteinS, KlieschS, NieschlagE (1999b) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol 50:629–635
BettendorfM, HeinrichUE, SchönbergDK, Grulich-HennJ (1997) Short-term, high dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature. Eur J Pediatr 156:911–915
BhasinS, PencinaM, JasujaGK, TravisonTG, CovielloA, OrwollE, WangPY, NielsonC, WuF, TajarA, LabrieF, VesperH, ZhangA, UlloorJ, SinghR, D'AgostinoR, VasanRS (2011) Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 96:2430–2439
BojesenA, JuulS, GravholtCH (2003) Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 88:622–626
BojesenA, StockholmK, JuulS, GravholtCH (2011) Socioeconomic trajectories affect mortality in Klinefelter syndrome. J Clin Endocrinol Metab 96:2098–2104
BrabrandS, FossåSD, CvancarovaM, LehneG (2011) Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals. BJU Int 107:1080–1087
BrownD, ButlerCGE, KelnarCJH, WuFCW (1995) A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys. Arch Dis Child 73:141–145
BüchterD, BehreHM, KlieschS, NieschlagE (1998) Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 149:298–303
BurrisAS, BanksSM, CarterCS, DavidsonJM, SherinsRJ (1992) A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogondadal men. J Androl 14:297–304
CalofOM, SinghAB, LeeML, KennyAM, UrbanRJ, TenoverJL, BhasinS (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457
CharnyCW, GordonJA (1978) Testosterone rebound therapy: a neglected modality. Fertil Steril 29:64–68
ComhaireF, SchoonjansF, AbelmassihR, GordtsS, CampoR, DhontM, MilingosS, GerrisJ (1995) Does treatment with testosterone undecanoate improve the in-vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (Results of a double blind study). Hum Reprod 10:2600–2602
CunninghamGR, HirshkowitzM, KorenmanSG, KaracanI (1990) Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 70:792–797
DeckerR, PratschC-J, SippellWG (2002) Combined treatment with testosterone (T) and ethinylestradiol (EE2) in constitutionally tall boys: is treatment with T plus EE2 more effective in reducing final height in tall boys than T alone?J Clin Endocrinol Metab 87:1634–1639
de LangeWE, SnoepMC, DoorenbosH (1979) The effect of short-term testosterone treatment in boys with delayed puberty. Acta Endocrinol 91:177–183
DepenbuschM, von EckardsteinS, SimoniM, NieschlagE (2002) Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with hCG alone. Eur J Endocrinol 147:617–624
de RondeW (2009) Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 24:425–428
de WaalWJ, VreeburgJTM, BekkeringF, de JongFH, de Muinck Keizer-SchramaSMPF, DropSLS, WeberRFA (1995) High dose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood?Clin Endocrinol 43:87–95
DropSLS, de WaalWJ, de Muinck Keizer-SchramaSMPF (1998) Sex steroid treatment of constitutionally tall stature. Endocr Rev 19:540–558
EndresW, ShinYS, RiethM, BlockT, SchmiedtE, KnorrD (1987) Priapism in Fabry's disease during testosterone treatment. Klin Wschr 65:925
FranchiF, LuisiM, KicovicPM (1978) Long-term study of oral testosterone undecanoate in hypogonadal males. Int J Androl 1:270–278
GoorenLJG (1994) A ten year safety study of the oral androgen testosterone undecanoate. J Androl 15:212–215
HaringR, VölzkeH, StevelingA, KrebsA, FelixSB, SchöflC, DörrM, NauckM, WallaschofskiH (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J 31:1494–1501
HendriksAE, BoellaardWP, van CasterenNJ, RomijnJC, de JongFH, BootAM, DropSL (2010) Fatherhood in tall men treated with high-dose sex steroids during adolescence. J Clin Endocrinol Metab 95:5233–5240
IchiokaK, UtsunomiyaN, KoheiN, UedaN, InoueK, TeraiA (2006) Testosterone-induced priapism in Klinefelter syndrome. Urology 67:622.e17–622.e18
IshiiT, SasakiG, HasegawaT, SatoS, MatsuoN, OgataT (2004) Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis. J Urol 172:319–324
JockenhövelF (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48:590–596
KamischkeA, NieschlagE (1999) Analysis of medical treatment of male infertility. Hum Reprod 14:1–23
KühnertB, ByrneM, SimoniM, KöpckeW, GerssJ, LemmnitzG, NieschlagE (2005) Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol 153:317–326
LanfrancoF, KamischkeA, ZitzmannM, NieschlagE (2004) Klinefelter's syndrome. Lancet 364:273–283
LaughlinGA, Barrett-ConnorE, BergstromJ (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75
LeeKK, BermanN, AlexanderGM, HullL, SwerdloffRS, WangC (2003) A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 25:688–698
LemckeB, ZentgrafJ, BehreHM, KlieschS, BramswigJH, NieschlagE (1996) Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J Clin Endocrinol Metab 81:296–301
LuboshitzkyR, AvivA, HefetzA, HererP, Shen-OrrZ, LavieL, LavieP (2002) Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 87:3394–3398
LuisiM, FranchiF (1980) Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 3:305–308
McNicholasT, OngT (2006) Review of Testim gel. Expert Opin Pharmacother 7:477–484
MoralesA, JohnstonB, HeatonJPW, LundieM (1997) Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157:849–854
NieschlagE, CüppersHJ, WiegelmannW, WickingsEJ (1976) Bioavailability and LH suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7:148
NieschlagE, BehreHM, BouchardP, CorralesJJ, JonesTH, StallaGK, WebbSM, WuFC (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10:409–419
NieschlagE, BehreHM, NieschlagS (eds) (2010) Andrology. Male Reproductive Health and Dysfunction, 3rd edn. Springer-Verlag, Berlin
OhlssonC, VandenputL (2009) The role of estrogens for male bone health. Eur J Endocrinol 160:883–889
PedersenMF, MollerS, KrabbeS, BennettP (1986) Fundamental voice frequency measured by electroglottography during continuous speech. A new exact secondary sex characteristic in boys in puberty. Int J Ped Otohinol 11:21–27
PuschHH (1989) Oral treatment of oligozoospermia with testosterone-undecanoate: results of a double-blind-placebo-controlled trial. Andrologia 21:76–82
RaynaudJP, AugèsM, LiorzouL, TurlierV, LauzeC (2009) Adhesiveness of a new testosterone-in adhesive matrix patch after extreme conditions. Int J Pharmacol 375:28–32
RogolAD (2005) New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother 6:1319–1336
RolfC, von EckardsteinS, KokenU, NieschlagE (2002) Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur J Endocrinol 146:505–511
RosenRC, AraujoAB, ConnorMK, GerstenbergerEP, MorgentalerA, SeftelAD, MinerMM, ShabsighR (2011) The NERI Hypogonadism Screener: psychometric validation in male patients and controls. Clin Endocrinol 74:248–256
RosenfeldRG, NorthcraftGB, HintzRL (1982) A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics 69:681–687
RuchW, JennyP (1989) Priapism following testosterone administration for delayed male puberty. Am J Med 86:256
Schulte-BeerbühlM, NieschlagE (1980) Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 33:201–203
ShabsighR (1997) The effects of testosterone on the cavernous tissue and erectile function. World J Urol 15:21–26
ShoresMM, MatsumotoAM, SloanKL, KivlajamDR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660–1665
SkakkebaekNE, BancroftJ, DavidsonDW, WarnerP (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol 14:49–61
SnyderPJ (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972
SnyderPJ, LawrenceDA (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51:1335–1339
SokolRZ, PalaciosA, CampfieldLA, SaulC, SwerdloffRS (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37:425–430
VermeulenA, VerdonckG (1992) Representatives of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 74:939–942
von EckardsteinS, NieschlagE (2002) Treatment of male hypogonadism with testosterone undecanoate injection at extended intervals of 12 weeks: a phase II study. J Androl 23:419–425
WangC, AlexanderG, BermanN, SalehianB, DavidsonT, McDonaldV, SteinerB, HullH, CallegariC, SwerdloffR (1996) Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 81:3578–3583
WangC, CunninghamG, DobsA (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085–2098
WangC, NieschlagE, SwerdloffR, BehreHM, HellstromWJ, GoorenLJ, KaufmanJM, LegrosJJ, LunenfeldB, MoralesA, MorleyJE, SchulmanC, ThompsonIM, WeidnerW, WuFC (2008) Investigation, treatment and monitoring of late onset hypogonadism in males. Eur J Endocrinol 159:507–514
WangC, HarnettM, DobsAS, SwerdloffRS (2010) Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl 31:457–465
WarneDW, DecosterdG, OkadaH, YanoY, KoideN, HowlesCM (2009) A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormones and human chorionic gonadotropin. Fertil Steril 92:594–604
WhitworthJA, ScogginsBA, AndrewsJ, WilliamsonPM, BrownMA (1992) Haemodynamic and metabolic effects of short term administration of synthetic sex steroids in humans. Clin Exp Hypertens 14:905–922
WittertGA, ChapmanIM, HarenMT, MackintoshS, CoatesP, MorleyJE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 58:618–625
World Health Organization, Task Force on the Diagnosis and Treatment of Infertility (1989) Mesterolone and idiopathic male infertility: a double-blind study. Int J Androl 12:254–264
World Health Organization, NieschlagE, WangC, HandelsmanDJ, SwerdloffRS, WuF, Einer-JensenN, WaitesG (1992) Guidelines for the Use of Androgens. WHO, Geneva
ZelissenPMJ, StrickerBHC (1988) Severe priapism as a complication of testosterone substitution therapy. Am J Med 85:273
ZitzmannM, NieschlagE (2001) Testosterone levels in healthy men and their relation to behavioural and physical characteristics: facts and constructs. Eur J Endocrinol 144:183–197
ZitzmannM, NieschlagE (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92:3844–3853
ZitzmannM, RolfC, BruneM, ViethV, NieschlagE (2002) Monitoring bone density in hypogonadal men by quantitative phalangeal ultrasound. Bone 31:422–429
ZitzmannM, DepenbuschM, GromollJ, NieschlagE (2003) Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88:2049–2054
ZitzmannM, FaberS, NieschlagE (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335–4343